PO.6.126 Anti-rituximab antibodies demonstrate neutralising capacity, associate with lower circulating drug levels and early relapse in patients undergoing treatment for systemic lupus erythematosus

• N Kharlamova,
• D Isenberg,
• N Dunn,
• A Fogdell-Hahn,
• C Wincup,
• E Jury,
• C Ciurtin,
• C Ruetsch-Chelli,
• A Manouchehrinia,
• M Naja,
• B Seitz-Polski

Affiliations

N Kharlamova

1Department of Medicine

D Isenberg

Centre for Reumatology, Division of Medicine, The Middlesex Hospital and University College London, 4th Floor Arthur Stanley House, 40–50 Tottenham Street, London W1T 4NJ, UK

N Dunn

Primary Medical Care Group, University of Southampton School of Medicine, Aldermoor Health Centre, Southampton, UK

A Fogdell-Hahn

Karolinska Institutet, Department of Clinical Neuroscience, Division of Neurology R54, Karolinska University Hospital Huddinge, Sweden

C Wincup

1Department of Rheumatology, University College London, UK

E Jury

1University College London – Rheumatology and Adolescent Rheumatology, London, UK

C Ciurtin

2University College London Hospital – Department of Rheumatology, London, UK

C Ruetsch-Chelli

4Laboratoire d’Immunologie, CHU de Nice, Université Côte d’Azur, Nice, FRANCE

A Manouchehrinia

2Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, SWEDEN

M Naja

1Department of Rheumatology, University College London Hospital, LONDON, UK

B Seitz-Polski

4Laboratoire d’Immunologie, CHU de Nice, Université Côte d’Azur, Nice, FRANCE